MedPath

Acetazolamide

Generic Name
Acetazolamide
Drug Type
Small Molecule
Chemical Formula
C4H6N4O3S2
CAS Number
59-66-5
Unique Ingredient Identifier
O3FX965V0I
Background

One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Indication

For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma

Associated Conditions
Acute angle-closure glaucoma, Edema, Familial periodic paralysis, Generalized Tonic-Clonic Seizures, Metabolic Alkalosis, Open Angle Glaucoma (OAG), Other and unspecified effects of high altitude, Cystine renal calculi, Drug-induced edema, Nonuveitic secondary glaucoma, Salicylate intoxication
Associated Therapies
Urine alkalinization therapy

Acetazolamide Per os for Decompensation of Heart Failure

Phase 4
Recruiting
Conditions
Chronic Heart Failure
Interventions
First Posted Date
2023-04-07
Last Posted Date
2024-11-05
Lead Sponsor
Samara State Medical University
Target Recruit Count
400
Registration Number
NCT05802849
Locations
🇷🇺

Samara state medical university, Samara, Russian Federation

Patient-centered and Neurocognitive Outcomes with Acetazolamide for Sleep Apnea

Phase 2
Recruiting
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Placebo
First Posted Date
2023-04-07
Last Posted Date
2024-11-05
Lead Sponsor
University of California, San Diego
Target Recruit Count
60
Registration Number
NCT05804084
Locations
🇺🇸

UC San Diego; Altman Clinical and Translational Research Institute Building, La Jolla, California, United States

Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health

Phase 2
Recruiting
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Placebo
Device: Continuous Positive Airway Pressure
First Posted Date
2022-11-15
Last Posted Date
2025-02-14
Lead Sponsor
University of California, San Diego
Target Recruit Count
46
Registration Number
NCT05616260
Locations
🇺🇸

UC San Diego; Altman Clinical and Translational Research Institute Building, La Jolla, California, United States

Acetazolamide on REM OSA

Phase 1
Active, not recruiting
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Placebo oral capsule
First Posted Date
2022-10-21
Last Posted Date
2025-02-06
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
10
Registration Number
NCT05589792
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Sleep Disordered Breathing With Opioid Use

Phase 1
Recruiting
Conditions
Sleep Apnea
Opioid Use
Sleep Disordered Breathing
Interventions
Other: Hyperoxia
First Posted Date
2022-10-21
Last Posted Date
2024-08-19
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
150
Registration Number
NCT05589753
Locations
🇺🇸

John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States

Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance

Phase 4
Completed
Conditions
High Altitude Effects
Interventions
First Posted Date
2022-10-12
Last Posted Date
2024-03-12
Lead Sponsor
University of Waterloo
Target Recruit Count
15
Registration Number
NCT05575180
Locations
🇨🇦

University of Waterloo, Waterloo, Ontario, Canada

Acetazolamide in Persons With Type 1 Diabetes - Dose Finding

Phase 1
Completed
Conditions
Type 1 Diabetes
Interventions
First Posted Date
2022-07-25
Last Posted Date
2025-05-15
Lead Sponsor
University of California, San Diego
Target Recruit Count
12
Registration Number
NCT05473364
Locations
🇺🇸

UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Phase 1
Active, not recruiting
Conditions
Tumor
Melanoma
Metastatic Melanoma
Interventions
First Posted Date
2022-07-22
Last Posted Date
2025-04-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
21
Registration Number
NCT05470283
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment

Phase 4
Completed
Conditions
Acute Heart Failure
Diuretics Drug Reactions
Interventions
Diagnostic Test: UNa measurement after intravenous loop diuretic bolus
Other: Usual AHF care
Other: Maintenance infusion
Other: Intravenous hypertonic saline
Other: Switch to oral diuretic therapy
First Posted Date
2022-06-09
Last Posted Date
2024-07-23
Lead Sponsor
Vrije Universiteit Brussel
Target Recruit Count
107
Registration Number
NCT05411991
Locations
🇧🇪

Jessa Hospital, Hasselt, Limburg, Belgium

🇧🇪

University Hospital Brussels, Jette, Brussels, Belgium

Pharmacological Countermeasures for High Altitude

Phase 4
Active, not recruiting
Conditions
Hypobaric Hypoxia
Interventions
First Posted Date
2022-03-29
Last Posted Date
2025-03-26
Lead Sponsor
United States Army Research Institute of Environmental Medicine
Target Recruit Count
18
Registration Number
NCT05300477
Locations
🇺🇸

USARIEM, Natick, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath